Pay in 4 interest-free payments of $24.00 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
NSC59984 as a promising lead compound for anticancer therapy that acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling
Granuloma faciale successfully treated with ingenol mebutate
Formula: C18H20O2
Surapaneni S
InChiKey: XKJQVUIXSBOCPP-UHFFFAOYSA-N
PJ34 - CAS# 344458-19-1 e O-desmethyl Mebeverine acid NSC59984 as a promising leadPJ 34 is a novel and potent PARP 1 inhibitor with potential anticancer activity. PJ34 has a high affinity for PARP 1 (IC(50) = 20 nM). PJ 34 inhibits PARP 1 expression and ERK phosphorylation in glioma conditioned brain microvascular endothelial cells. PJ 34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest. PJ 34 reduce cell inflammation and damage that follow PARP 1 overexpression. PJ 34 negatively
US$ 38.00
US$ 69.00
US$ 169.00
US$ 38.00
US$ 99.00
US$ 69.00
US$ 185.00
US$ 411.12
US$ 99.00
US$ 99.00
US$ 89.00
US$ 69.00
US$ 69.00
US$ 38.00
US$ 119.00
US$ 119.00
US$ 119.00